Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

Study Overview
=================
Brief Summary
-----------------
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled, FTIH study, that includes both single-ascending and multiple-ascending dose phase to assess the safety, tolerability, and pharmacokinetic (PK)/pharmacodynamic (PD) attributes of GSK3732394 in healthy subjects. The data gathered in this study will further enable clinical development of GSK3732394 in HIV-infected subjects. Approximately 72 healthy subjects will be randomized in the FTIH study. Part 1 will be the single ascending dose (SAD) phase and Part 2 will be the multiple ascending dose (MAD) phase. Each subject in the SAD cohort will receive a single dose of blinded GSK3732394 or blinded placebo (PBO) in 6:2 ratio. Part 1 will consist of five ascending single-dose cohorts with an additional expansion cohort included as needed. Part 2 will consist of up to three ascending repeat-dose cohorts (MAD Cohorts 1, 2, and 3), randomized to four weekly doses of blinded GSK3732394 or blinded PBO in 6:2 ratio to be administered on Days 1, 8, 15, and 22.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3732394 in Healthy Participants

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: GSK3732394
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must be 18 to 50 years of age inclusive, at the time of signing the informed consent. Subjects who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. Subjects who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions Body mass index within the range 19 to 30 kilogram per meter square (kg/m2) inclusive, in addition to a weight range of 50kg to 100kg. Male and female healthy volunteers. All male subjects must agree to use contraception during the treatment period and for at least 100 days after the last dose of study treatment and refrain from donating sperm during this period. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies; Not a woman of childbearing potential (WOCBP), A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 28 days prior to first dose, and 40 days after, the last dose of study treatment. Capable of giving signed informed consent. A signed and dated written informed consent must be completed prior to the subject's entry into the study. Exclusion Criteria: Subject has a history or presence of cardiovascular, dermatological, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data. Subject has abnormal blood pressure (as determined by the investigator). Subject had symptomatic herpes zoster within 3 months prior to screening. Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, TB testing that includes a positive tuberculin skin test [TST]; defined as a skin induration greater than 5 millimeter [mm] at 48 to 72 hours,and regardless of Bacillus Calmette-Guerin [BCG] or other vaccination history) or a positive (not indeterminate) QuantiFERON-TB Gold test. Subjects with lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. Subjects who had breast cancer within the past 10 years. Subjects who had history of severe injection site reaction (i.e., required emergency care or hospitalization) following any prior injection, including reaction to vaccines. Subjects with history of clinically significant allergy or prior hypersensitivity including those with a documented yeast allergy. Subjects with history of, or current concern for, a chronic immune deficiency disorder including, but not limited to: diabetes, sickle cell anemia, and malnutrition. Subjects having alanine transaminase (ALT) greater than 1.1 x upper limit of normal (ULN). Subjects with Hemoglobin levels below the normal range. Subjects with Platelet count <130,000 per cubic millimeters. Subjects with Creatinine clearance (CrCL) <90 milliliters per minute. Subjects with bilirubin greater than 1.1xULN (isolated bilirubin greater than 1.1xULN is acceptable if bilirubin is fractionated and direct bilirubin greater than 35%). Subjects who has current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Subjects having Fridericia QT correction formula (QTcF) greater than 450 milliseconds (msec). Subjects who had intended use of over-the-counter or prescription medication within 7 days prior to dosing. Subjects who had live vaccine(s) within 1 month prior to screening, or plans to receive such vaccines during the study. Subjects who had treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing. Subjects who had exposure to immune-modulating medications (including corticosteroids) within 30-days of Screening. Subjects whose participation in the study would result in loss of blood or blood products in excess of 500 (milliliter) mL within 56 days. Subjects who had Exposure to more than four new chemical entities within 12 months prior to the first dosing day. Subjects with current enrollment or past participation within the last 30 days before signing of consent in this or any other clinical study involving an investigational study intervention or any other type of medical research. Absolute CD4+ T-cell count and CD4 percent (CD4%) outside of the normal range for the reference laboratory (to be confirmed at baseline, e.g., Day -1). Subjects who had presence of Hepatitis B surface antigen (HBsAg) at screening. Subjects with positive Hepatitis C antibody test result at screening. Subjects with positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention. Subjects with positive pre-study drug/alcohol screen. Subjects with positive human immunodeficiency virus (HIV) antibody test. Subjects with history of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of greater than 14 units. One unit is equivalent to 8 grams (g) of alcohol: a half pint ( 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits. Subjects with urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6 months prior to screening. Subjects who has sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: In Part 1 of the study each of the subjects in the SAD cohorts (SAD Cohorts 1-5; SAD Cohort 6 is a possible expansion cohort that will be added as needed) will receive a single dose of blinded GSK3732394 or blinded PBO (GSK3732394: PBO = 6:2), per their randomization assignment. Part 2 will consist of up to three ascending repeat-dose cohorts (MAD Cohorts 1, 2, and 3), each with 8 subjects (blinded GSK3732394: blinded PBO = 6:2) will receive four weekly doses of GSK3732394 or PBO on Days 1, 8, 15, and 22.
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Part 1,Cohort 1:Subjects receiving blinded GSK3732394 10mg/PBO<br>GSK3732394 10 milligram (mg) or PBO will be administered by subcutaneous (SC) injection to the subjects. | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>Drug: Placebo<br>* Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.<br>|
| Experimental: Part 1,Cohort 2:Subjects receiving blinded GSK3732394 40mg/PBO<br>GSK3732394 40 mg or PBO will be administered by SC injection to the subjects. This is projected dose, dose will be based on PK/PD results from preceding dosing cohorts. | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>Drug: Placebo<br>* Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.<br>|
| Experimental: Part1,Cohort 3:Subjects receiving blinded GSK3732394 130mg/PBO<br>GSK3732394 130 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 3 will be based on PK/PD results from preceding dosing cohorts. | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>|
| Experimental: Part1,Cohort 4:Subjects receiving blinded GSK3732394 350mg/PBO<br>GSK3732394 350 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 4 will be based on PK/PD results from preceding dosing cohorts. | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>Drug: Placebo<br>* Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.<br>|
| Experimental: Part1,Cohort5: Subjects receiving blinded GSK3732394 600mg/PBO<br>GSK3732394 600 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 5 will be based on PK/PD results from preceding dosing cohorts. | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>Drug: Placebo<br>* Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.<br>|
| Experimental: Part1,Cohort6: Subjects receiving blinded GSK3732394 800mg/PBO<br>GSK3732394 800 mg or PBO will be administered by SC injection to the subjects. This is a projected dose and will be given if necessary. The dose administered in Part 1, Cohort 6 (if necessary) will be based on PK/PD results from preceding dosing cohorts. | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>Drug: Placebo<br>* Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.<br>|
| Experimental: Part2,Cohort1: Subjects receiving blinded GSK3732394 130mg/PBO<br>GSK3732394 130 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The dose administered in Part 2, Cohort 1 will be based on PK/PD results from preceding dosing cohorts. | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>Drug: Placebo<br>* Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.<br>|
| Experimental: Part2,Cohort2: Subjects receiving blinded GSK3732394 400mg/PBO<br>GSK3732394 400 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 2 will be based on PK/PD results from preceding dosing cohorts. | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>Drug: Placebo<br>* Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.<br>|
| Experimental: Part2,Cohort3: Subjects receiving blinded GSK3732394 600mg/PBO<br>GSK3732394 600 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 3 will be based on PK/PD results from preceding dosing cohorts and will not exceed the maximum exposure observed in SAD (Part 1). | Drug: GSK3732394<br>* It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL<br>Drug: Placebo<br>* Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part 1: Number of Participants With Non-serious Adverse Event (SAEs) and SAEs | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death and is life-threatening which requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability or incapacity and birth defect or congenital anomaly, or any other situation that require medical or scientific judgement. Number of participants with common more than or equal to (>=)5 percent (%) non-serious AEs and SAEs are presented. | Up to Day 28 | 
| Part 2: Number of Participants With Non-SAEs and SAEs | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death and is life-threatening which requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability or incapacity and birth defect or congenital anomaly, or any other situation that require medical or scientific judgement. All AEs were planned to be collected from the start of treatment until the follow-up visit. | Up to Day 49 | 
| Part 1: Number of Participants With Clinical Chemistry Parameters by Maximum Grade Increase Post-Baseline | Blood samples were collected for the analysis of following clinical chemistry parameters: Glucose, alkaline phosphatase, alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin, total bilirubin, calcium, creatinine, potassium, lipase and sodium. The clinical chemistry abnormalities were graded using the Division of Acquired immunodeficiency syndrome (DAIDS) criteria and grades were derived based on numeric criteria as defined in DAIDS Version 2.1 and did not take into consideration of clinical signs or symptoms. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severe condition. Baseline is defined as the latest pre-dose assessment. Number of participants with clinical chemistry parameters by maximum grade increase post-Baseline is presented. | Up to Day 28 | 
| Part 2: Number of Participants With Clinical Chemistry Parameters by Maximum Grade Increase Post-Baseline | Blood samples were planned to be collected for the analysis of the following clinical chemistry parameters: Glucose, alkaline phosphatase, ALT, amylase, AST, direct and total bilirubin, calcium, creatinine, potassium, lipase and sodium. Baseline is defined as the latest pre-dose assessment. | Up to Day 49 | 
| Part 1: Number of Participants With Hematology Parameters by Maximum Grade Increase Post-Baseline | Blood samples were collected for the analysis of following hematology parameters: Cluster of differentiation (CD) 4 cells, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The hematology abnormalities were graded using the DAIDS criteria and grades were derived based on numeric criteria as defined in DAIDS Version 2.1 and did not take into consideration of clinical signs or symptoms. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severe condition. Baseline is defined as the latest pre-dose assessment. Number of participants with hematology parameters by maximum grade increase post-Baseline is presented. | Up to Day 28 | 
| Part 2: Number of Participants With Hematology Parameters by Maximum Grade Increase Post-Baseline | Blood samples were planned to be collected for the analysis of the following hematology parameters: CD4 cells, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. Baseline is defined as the latest pre-dose assessment. | Up to Day 49 | 
| Part 1: Number of Participants With Urinalysis Parameters by Any Increase in Discrete or Character Values Post Baseline | Urine samples were collected for the analysis of urine parameters including bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, protein and urobilinogen. The urinalysis abnormalities were graded using the DAIDS criteria and grades were derived based on numeric criteria as defined in DAIDS Version 2.1 and did not take into consideration of clinical signs or symptoms. Baseline is defined as the latest pre-dose assessment. Number of participants with urinalysis parameters by any increase in discrete or character values post Baseline is presented. | Up to Day 28 | 
| Part 2: Number of Participants With Urinalysis Parameters by Any Increase in Discrete or Character Values Post Baseline | Urine samples were planned to be collected for the analysis of urine parameters including bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, protein and urobilinogen. Baseline is defined as the latest pre-dose assessment. | Up to Day 49 | 
| Part 1: Number of Participants With Worst Case Pulse Rate Post Baseline | Pulse rate was measured in a semi-supine position after 5 minutes of rest. Participants are counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose value category are unchanged (e.g., High to High), or whose value became within range, are recorded in the To within Range or No Change category. Participants with missing Baseline value are assumed to have within range value. Participants were counted twice if the participant had both values that changed 'To Low' and 'To High'. Baseline is defined as the latest pre-dose assessment. Number of participants with pulse rate change to low or to high and no change post Baseline is presented. | Up to Day 28 | 
| Part 2: Number of Participants With Worst Case Pulse Rate Post Baseline | Pulse rate was planned to be measured in a semi-supine position after 5 minutes of rest. Baseline is defined as the latest pre-dose assessment. | Up to Day 49 | 
| Part 1: Change From Baseline in Body Temperature | Body temperature was measured in a semi-supine position after 5 minutes of rest. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value. | Baseline and at Day 1 (1, 2, 4, 8, 12 hours), Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: Change From Baseline in Body Temperature | Body temperature was planned to be measured in a semi-supine position after 5 minutes of rest. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. | Baseline and Up to Day 49 | 
| Part 1: Change From Baseline in Respiratory Rate | Respiratory rate was measured in a semi-supine position after 5 minutes of rest. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value. | Baseline and at Day 1 (1, 2, 4, 8, 12 hours), Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: Change From Baseline in Respiratory Rate | Respiratory rate was planned to be measured in a semi-supine position after 5 minutes of rest. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. | Baseline and Up to Day 49 | 
| Part 1: Number of Participants With Worst Case Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Post Baseline | SBP and DBP was measured in a semi-supine position after 5 minutes of rest. Participants are counted in the worst case category that their value changes to low, within range or no change, or high), unless there is no change in their category. Participants whose value category are unchanged (e.g., High to High), or whose value became within range, are recorded in the To within Range or No Change category. Participants with missing Baseline value are assumed to have within range value. Participants were counted twice if the participant had both values that changed 'To Low' and 'To High'. Baseline is defined as the latest pre-dose assessment. Number of participants with SBP and DBP change to low and to high and no change post Baseline is presented. | Up to Day 28 | 
| Part 2: Number of Participants With Worst Case SBP and DBP Post Baseline | SBP and DBP was planned to be measured in a semi-supine position after 5 minutes of rest. Baseline is defined as the latest pre-dose assessment. | Up to Day 49 | 
| Part 1: Number of Participants With Clinical Significant Abnormal Electrocardiogram (ECG) Findings | A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of 5 minutes. Twelve lead ECGs were obtained by using an automated ECG machine. Number of participants with clinical significant abnormal ECG findings are presented. | Pre-dose, 4, 12 hours on Day 1, 24 hours on Day 2, Days 8, 14, 17 and 28 | 
| Part 2: Number of Participants With Clinical Significant Abnormal ECG Findings | 12-lead ECG recordings was planned to be measured. | Up to Day 49 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part 1: Area Under the Plasma Concentration Time Curve From Zero to t (AUC[0-t]) Following Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3732394. PK parameters were analyzed using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: AUC(0-t) After Repeat Dosing of GSK3732394 in First Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 1 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 2, 3, 4, 5, 6 and 7 | 
| Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) Following Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for PK analysis of GSK3732394. PK parameters were analyzed using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: AUC(0-infinity) After Repeat Dosing of GSK3732394 in First Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 1 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 2, 3, 4, 5, 6 and 7 | 
| Part 1: Maximum Observed Concentration (Cmax) Following Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for PK analysis of GSK3732394. PK parameters were analyzed using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: Cmax After Repeat Dosing of GSK3732394 in First Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 1 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 2, 3, 4, 5, 6 and 7 | 
| Part 2: Cmax After Repeat Dosing of GSK3732394 in Last Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 23, 24, 25, 26, 27 and 28 | 
| Part 1: Time of Occurrence of Cmax (Tmax) After Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for PK analysis of GSK3732394. PK parameters were calculated using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: Tmax After Repeat Dosing of GSK3732394 in First Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 1 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 2, 3, 4, 5, 6 and 7 | 
| Part 2: Tmax After Repeat Dosing of GSK3732394 in Last Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 23, 24, 25, 26, 27 and 28 | 
| Part 1: Lag Time Before Observation of Drug Concentrations (Tlag) After Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for PK analysis of GSK3732394. PK parameters were calculated using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: Tlag After Repeat Dosing of GSK3732394 in First Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 1 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 2, 3, 4, 5, 6 and 7 | 
| Part 1: Last Observable Concentration (Clast) After Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for PK analysis of GSK3732394. PK parameters were analyzed using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 1: Time of Last Observable Concentration (Tlast) After Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for PK analysis of GSK3732394. PK parameters were analyzed using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 1: Apparent Terminal Phase Half-life (t1/2) After Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for PK analysis of GSK3732394. PK parameters were analyzed using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: T1/2 After Repeat Dosing of GSK3732394 in Last Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 23, 24, 25, 26, 27 and 28 | 
| Part 1: Apparent Clearance (CL/F) After Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for PK analysis of GSK3732394. PK parameters were analyzed using standard non-compartmental analysis. | Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: CL/F After Repeat Dosing of GSK3732394 in Last Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 23, 24, 25, 26, 27 and 28 | 
| Part 2: Area Under the Concentration Time Curve at Steady State Within the Dosing Interval (AUC[0-tau]) After Repeat Dosing of GSK3732394 in Last Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 23, 24, 25, 26, 27 and 28 | 
| Part 2: Trough Concentration (Ctrough) After Repeat Dosing of GSK3732394 in Last Week | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. | Day 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 23, 24, 25, 26, 27 and 28 | 
| Part 2: Accumulation Ratio Using AUC(0-tau) (RAUC[0-tau]) After Repeat Dosing of GSK3732394 | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. RAUC(0-tau) was planned to be calculated as the ratio of AUC(0-tau) on week 4 to AUC(0-tau) on week 1 . | Days 1 and 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 2, 3, 4, 5, 6, 7, 23, 24, 25, 26, 27 and 28 | 
| Part 2: Accumulation Ratio Using Cmax (RCmax) After Repeat Dosing of GSK3732394 | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. RCmax was planned to be calculated as the ratio of Cmax on Week 4 to Cmax on Week 1. | Days 1 and 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 2, 3, 4, 5, 6, 7, 23, 24, 25, 26, 27 and 28 | 
| Part 2: Accumulation Ratio Using Ctrough (RCtrough) After Repeat Dosing of GSK3732394 | Blood samples were planned to be collected at indicated time points for PK analysis of GSK3732394. RCtrough was planned to be calculated as the ratio of Ctrough on Week 4 to Ctrough on Week 1. | Days 1 and 22 (pre-dose, 0.5, 1, 2, 4, 8 and 12 hours), Days 2, 3, 4, 5, 6, 7, 23, 24, 25, 26, 27 and 28 | 
| Part 1: Change From Baseline in Percent of CD4 Receptor Occupancy (RO) After Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for Pharmacodynamic (PD) analysis of CD4 receptors occupied by GSK3732394 on CD4+ T cells. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value. | Baseline, Day 1 (0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: Change From Baseline in Percent of CD4 RO After Multiple Dose Administration of GSK3732394 | Blood samples were planned to be collected at indicated time points for PD analysis of CD4 receptors occupied by GSK3732394 on CD4+ T cells. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. | Baseline and up to Day 49 | 
| Part 1: Change From Baseline in CD3+ Cells Following Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for analysis of CD3+ cells. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value. | Baseline, Days 2, 3, 5, 8, 11, 14, 17, 21, 24 and 28 | 
| Part 2: Change From Baseline in CD3+ Cells Following Multiple Dose Administration of GSK3732394 | Blood samples were planned to be collected at indicated time points for analysis of CD3+ cells. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. | Baseline and up to Day 49 | 
| Part 1: Change From Baseline in CD4+ Cells Following Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for analysis of CD4+ cells. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value. | Baseline, Days 2, 3, 5, 8, 11, 14, 17, 21, 24 and 28 | 
| Part 2: Change From Baseline in CD4+ Cells Following Multiple Dose Administration of GSK3732394 | Blood samples were planned to be collected at indicated time points for analysis of CD4+ cells. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. | Baseline and up to Day 49 | 
| Part 1: Change From Baseline in CD8+ Cells Following Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for analysis of CD8+ cells. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value. | Baseline, Days 2, 3, 5, 8, 11, 14, 17, 21, 24 and 28 | 
| Part 2: Change From Baseline in CD8+ Cells Following Multiple Dose Administration of GSK3732394 | Blood samples were planned to be collected at indicated time points for analysis of CD8+ cells. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. | Baseline and up to Day 49 | 
| Part 1: Change From Baseline in CD4+ Cell Median Fluorescence Intensity (MFI) Following Single Dose Administration of GSK3732394 | Blood samples were collected at indicated time points for analysis of CD4+ cell MFI. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value. | Baseline, Day 1 (0.5, 1, 2, 4, 8, 12 hours), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 21, 24 and 28 | 
| Part 2: Change From Baseline in CD4+ Cell MFI Following Multiple Dose Administration of GSK3732394 | Blood samples were planned to be collected at indicated time points for analysis of CD4+ cell MFI. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. | Baseline and up to Day 49 | 
| Part 1: Number of Participants With Anti-GSK3732394 Antibodies on Day 28 | Serum samples were collected to analyze antibodies against GSK3732394. The presence of anti-GSK3732394 antibodies was determined in serum samples using a validated bioanalytical method, which included a screening assay, confirmation assay and titer analysis. Positive samples were further characterized with additional assays to determine the specificity of the anti-GSK3732394 antibodies. Number of participants with presence of anti-GSK3732394 antibodies are presented. | Day 28 | 
| Part 2: Number of Participants With Anti-GSK3732394 Antibodies | Serum samples were planned to be collected to analyze antibodies against GSK3732394. | Up to Day 49 | 
| Part 1: Titer of Anti-drug Antibodies (ADAs) Against GSK3732394 on Day 28 | Serum samples were collected to analyze the titers of antibodies against GSK3732394. The presence of anti-GSK3732394 antibodies was determined in serum samples using a validated bioanalytical method, which included a screening assay, confirmation assay and titer analysis. Positive samples were further characterized with additional assays to determine the specificity of the anti-GSK3732394 antibodies. Positive samples were titrated to obtain the titers of antibodies. | Day 28 | 
| Part 2: Titer of ADAs Against GSK3732394 | Serum samples were planned to be collected to analyze the titers of antibodies against GSK3732394. | Up to Day 49 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DAIDS, FTIH, HIV-1, MAD, SAD